Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Summary of Contract Assets and Liabilities (Details)

v3.10.0.1
Revenue Recognition - Summary of Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract asset $ 86 $ 541
Long-term pharma contract asset 268 31
Total pharma contract asset 354 572
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 271 371
Long-term pharma capitalized commissions 650 171
Total pharma capitalized commissions 921 542
Contract with Customer, Liability [Abstract]    
Current pharma contract liability 927 1,406
Long-term pharma contract liability 1,652 283
Total pharma contract liability $ 2,579 $ 1,689